The Sonnet FHAB Mechanism of Action
Our modular FHAB construct utilizes a validated, targeted albumin-binding approach to deliver cytokine payloads with enhanced penetration, retention and local activation directly to the tumor.
Technology Platform
Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.
Technology Platform
Pipeline
Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates.
Pipeline
Leadership
The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.
TeamEmail Alerts
Stay informed and receive company updates straight to your inbox.